Physician profile
Usha Bhandari
NPI 1053057240
$687.05
in general payments reported to CMS, 2019-2025
12 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $60.72 · 2024: $347 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $162.02 | 2024 | Mylux Patient Kit With Mobile Device, Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply |
| Novartis Pharmaceuticals Corporation | $119.45 | 2024-2025 | |
| Pfizer INC. | $72.73 | 2024-2025 | |
| Glaxosmithkline, LLC. | $60.72 | 2023 | Arexvy |
| Lilly USA, LLC | $50.24 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $46.54 | 2025 | Verquvo |
| Novo Nordisk INC | $44.91 | 2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $44.78 | 2024 | Xarelto |
| Amgen INC. | $35.25 | 2024-2025 | Repatha |
| Dexcom, INC. | $21.48 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $18.63 | 2024 | Airsupra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.30 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.